News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CureLab Awarded Up To $ 7 Million National Institutes of Health (NIH) Grant


10/19/2005 5:09:04 PM

BOSTON--(BUSINESS WIRE)--Aug. 1, 2005--CureLab, Inc. a biotech company with offices in Massachusetts and California, today announced that it has been awarded a grant from the National Institute of Health (NIH) to continue its development work towards a vaccine against the influenza (flu) virus. CureLab has developed patent pending, proprietary technology that it believes will enable it to develop a vaccine that would be effective against all strains of the flu virus, both known and unknown. This award from the NIH is the first phase of a two-phase grant under the Small Business Innovation Research (SBIR) Bio Defense Program. CureLab expects that the total amount of this award will be seven million dollars.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES